Yttrium-90 Carbon Microspheres in Patients With Unresectable Colorectal Liver Metastases

Unresectable Colorectal Liver Metastases Clinical Trial

— NRT-uCRLM  

Official title:

Yttrium-90 Carbon Microspheres in Patients With Unresectable Colorectal Liver Metastases: A Multicentre, Prospective, Open-label, Single-arm Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05692037
• Other study ID #: CHANCE2303-NRT6003
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 28, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: January 2023
• Source: Zhongda Hospital
• Contact: Hai-Dong Zhu, MD
• Phone: +862583262224
• Email: zhuhaidong9509[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of yttrium-90 carbon microspheres in patients with unresectable colorectal liver metastases

Description:

The efficacy and safety of yttrium-90 carbon microspheres in patients with unresectable colorectal liver metastases remain unknown. This multicentre, prospective, open-label, single-arm trial is designed to evaluate the safety and efficacy of yttrium-90 carbon microspheres in patients with unresectable colorectal liver metastases. The primary endpoints are the progression-free survival rates of liver target lesions. While the secondary endpoints include the safety, tumor control, and the distribution characteristics of yttrium-90 carbon microspheres.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Eastern Cooperative Oncology Group performance status = 1;

2. Expected survival time = 3 months;

3. Confirmed liver metastasis of colorectal cancer;

4. Complete resection and no local recurrence of the primary colorectal cancer;

5. Intolerance, failure to the previous anti-tumor treatments or, or recurrence liver metastasis after surgical resection;

6. Without extrahepatic metastases, inoperable or refuse surgical resection;

7. At least one well defined tumor (RECIST 1.1);

8. Tumor burden = 50% of the total liver volume;

9. Child-Pugh score = 7;

10. Adequate organ function: ? Blood routine [no blood transfusion or colony-stimulating factor (G-CSF) treatment within 14 days]: absolute neutrophil count = 1.5 × 109/L; platelet = 75 × 109/L; hemoglobin = 90 g/L; ? Liver function: total bilirubin = 2 times upper limit of normal (ULN); alanine transaminase and aspartate aminotransferase = 5. 0 ULN; alkaline phosphatase = 2.5 ULN; Albumin > 30 g/L; ? Renal function: Cr = 1.5 ULN; creatinine clearance = 50 mL/min (calculated according to Cockcroft-Gault formula); ? Coagulation function: international normalized ratio, prothrombin time and activated partial thromboplastin time were less than 1.5 ULN; ? Cardiovascular function: left ventricular ejection fraction = 50%;

11. According to CTCAE 5.0 standard, all adverse events of previous systematic anti-cancer treatment have recovered to baseline or = 1 grade, [except for the following: neuropathy induced by previous anti-cancer treatment is stable (= 2 grade) and hair loss];

12. Women and men of childbearing age must agree to take strict and effective contraceptive measures during the study period and within 6 m after the end of the trial. Men are forbidden to donate sperm. The pregnancy test results of female patients of childbearing age during the screening period and within 24 hours before administration must be negative.

Exclusion Criteria:

1. With previous history of hepatic encephalopathy;

2. Severe pulmonary insufficiency (forced expiratory volume at one second / forced vital capacity < 50% or forced expiratory volume at one second /predicting value < 50% or maximum volume per minute < 50 L/min);Obvious chronic obstructive pulmonary disease or interstitial pneumonia;

3. Percentage of hepatopulmonary shunt > 10%, or the single lung radiation absorbed dose > 30 Gy;

4. With hepatic artery malformation and unable to intubate hepatic artery;

5. Tumor thrombus in main portal vein;

6. Have received radiotherapy or transcatheter arterial chemoembolization (patients who have received transcatheter arterial non-iodized oil chemoembolization are judged by researchers);

7. The last anti-tumor treatment (surgery, chemotherapy, immunotherapy, targeted therapy) was less than 4 weeks before the drug administration;

8. Clinical manifestations of portal hypertension, moderate-severe or refractory ascites, or decompensated liver cirrhosis;

9. Major surgery or severe trauma within 28 days before yttrium-90 administration;

10. Participated in other trial within 1 month before yttrium-90 administration;

11. Pregnant and lactating women;

12. Serious infections in active stage or need systematic treatment;

13. With positive results of HIV antibody test;

14. The researchers judge that there is unresolved toxicity from previous treatment and will continue to exist, which may endanger the safety of patients;

15. The researcher judged clinical or laboratory examination abnormality or other reasons.

Related Conditions & MeSH terms

• Liver Neoplasms
• Neoplasm Metastasis
• Unresectable Colorectal Liver Metastases

Intervention

Combination Product:
• Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres
Yttrium-90 carbon microspheres SIRT

Locations

Country	Name	City	State
China	Zhongda Hospital Southeast University	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Zhongda Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival Rate of Liver Target Lesions	Survival probability of patients without imaging progression of liver target lesions	3 months after yttrium-90 injection
Secondary	Adverse events	Rate of adverse events	Up to 24 months
Secondary	Yttrium-90 distribution	Assessed by SPECT-CT imaging in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.Ten Patients will be tested for the radioactivity of yttrium-90 in blood, urine, and feces (if available)	Within 24 hours
Secondary	Objective response rate (ORR)	Evaluated by the investigator and independent image review committee respectively (CTCAE 1.1)	Up to 24 months
Secondary	Duration of response (DOR)	Time without imaging progression, evaluated by the investigator and independent image review committee respectively (CTCAE 1.1)	Up to 24 months
Secondary	Hepatic progression-free survival (hPFS)	Time without imaging progression of liver target lesions, evaluated by the investigator and independent image review committee respectively (CTCAE 1.1)	Up to 24 months
Secondary	Time to progression (TTP)	Time with tumor progression, evaluated by the investigator and independent image review committee respectively (CTCAE 1.1)	Up to 24 months
Secondary	Progression-free survival (PFS)	Evaluated by the investigator and independent image review committee respectively (CTCAE 1.1)	Up to 24 months
Secondary	Overall survival (OS)	Survival time	Up to 24 months
Secondary	Disease control rate (DCR)	Probability of tumor control	Up to 24 months